After BMY's drop, cancer drug stocks set to move?

CNBCAfter BMY's drop, cancer drug stocks set to move?CNBCOn Friday, Bristol-Myers Squibb shares sank 6 percent after it unveiled findings for its immunotherapy Opdivo in the most common form of lung cancer, called non-squamous non-small cell lung cancer. The study showed the medicine helped some patients ...Lung cancer immunotherapy, from PD-1 knockout mice to clinical trialsSpeaking of ResearchSaturday at ASCO: Changes for Prostate Cancer & MelanomaMedscapeCancer Research UK appoints leading experts in surgery, children's cancers ...Cancer Research UKMedPage Todayall 69 news articles »

Share this post